Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial

Blood Cancer Journal · Published 2026-07-03 · DOI 10.1038/s41408-026-01542-7

Free full text

Authors (21)

Aurore Perrot, Cyrille Touzeau, Stéphane Minvielle, Cyrille Hulin, Denis Caillot, Salomon Manier, Xavier Leleu, Cécile Sonntag, Karim Belhadj, Bertrand Arnulf, Thomas Chalopin, Jean-Richard Eveillard, Martine Escoffre-Barbe, Lionel Karlin, Laure Vincent, Margaret Macro, Hervé Avet-Loiseau, Soraya Wuilleme, Ariane Boumendil, Jill Corre, Philippe Moreau

Abstract

DOAJ holds no abstract for this record.

Read the article at the publisher →

Publication details

Year

2026

Citation

Perrot, A., Touzeau, C., Minvielle, S., et al. (2026). Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial. Blood Cancer Journal. https://doi.org/10.1038/s41408-026-01542-7

Related articles

• Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients · Blood Cancer Journal · 2026 · Same journal
• Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma · Blood Cancer Journal · 2026 · Same journal
• Fixed-dose inotuzumab ozogamicin (INO) combined with Vincristine and Prednisone (VP) regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia (B-ALL): a multi-center, open-label, single-arm, prospective clinical study · Blood Cancer Journal · 2026 · Same journal
• Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study · Blood Cancer Journal · 2026 · Same journal
• Preclinical and clinical efficacy of the HDAC6 inhibitor ricolinostat in combination with BCR pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia · Blood Cancer Journal · 2026 · Same journal
• Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine · Blood Cancer Journal · 2026 · Same journal
• Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma · Blood Cancer Journal · 2026 · Same journal
• Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin · Blood Cancer Journal · 2026 · Same journal
• Arterial thrombosis and cancer: insights from observations in myeloproliferative neoplasms and CHIP · Blood Cancer Journal · 2026 · Same journal
• The efficacy, safety, and rationale of orelabrutinib combined with obinutuzumab (O2) as a first-line systemic treatment for marginal zone lymphoma · Blood Cancer Journal · 2026 · Same journal